Nanjing Leads Biolabs has announced that its Phase II clinical study of Opamtistomig, also known as LBL-024, will move into an expansion phase for first-line hepatocellular carcinoma treatment. The company said the decision follows positive efficacy signals from the study.

Opamtistomig is described as a proprietary bispecific antibody targeting PD-L1 and 4-1BB. The approach is being evaluated in patients with hepatocellular carcinoma, the most common primary form of liver cancer, in the first-line treatment setting.

Leads Biolabs, a Nanjing-based company listed under stock code 9887.HK, provided the update on Aug. 5, 2026. The announcement signals continued clinical development of LBL-024 as the company expands its Phase II evaluation.